Study of Safety and Efficacy of Talimogene Laherparepvec With Cisplatin and Radiotherapy for Treatment of Locally Advanced Head and Neck Cancer

Head and Neck Cancer Clinical Trial

Official title:

A Phase 3 Randomized Trial of Concurrent Cisplatin & Radiotherapy With Or Without ONCOVEX^GM-CSF In Previously Untreated Patients With Locally Advanced Squamous Cell Carcinoma Of The Head And Neck

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT01161498
• Other study ID #: 006/09
• Secondary ID: 20110130
• Status: Terminated
• Phase: Phase 3
• First received: July 12, 2010
• Last updated: January 14, 2016
• Start date: February 2011
• Est. completion date: October 2011

Study information

• Verified date: January 2016
• Source: BioVex Limited
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug AdministrationUnited Kingdom: Medicines and Healthcare Products Regulatory Agency
• Study type: Interventional

Clinical Trial Summary

This study is being conducted to learn about the safety and risks of using talimogene laherparepvec to treat patients with head and neck cancer and to see if talimogene laherparepvec and chemoradiation together can destroy the tumours versus the use of chemoradiation alone. This study may provide information on the usefulness of talimogene laherparepvec combined with chemoradiation as a future treatment for head and neck cancer.

Description:

The objective is to evaluate the efficacy and safety of treatment with chemoradiation (CRT) plus talimogene laherparepvec compared to CRT alone in previously untreated patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN) for which surgical resection is not clinical indicated. The efficacy endpoints of the study aim to demonstrate overall clinical benefit for patients treated with talimogene laherparepvec as compared to CRT alone.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 5
• Est. completion date: October 2011
• Est. primary completion date: October 2011
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Male or female = 18 years

2. Eastern Co-Operative Oncology Group (ECOG) Performance Status = 1

3. Histological evidence (from the primary lesion and/or lymph nodes) of squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, or larynx

4. Stage III or IV disease (T2N2-3M0, T3-4N1-3M0)

5. No evidence of distant metastases by computed tomography (CT) or positron emission tomography (PET)/CT scan

6. Life expectancy > 4 months

7. Neutrophil count = 2,000/mm^3

8. Platelet count = 100,000/mm^3

9. Hemoglobin = 10 g/dL

10. Bilirubin = 1.5 times upper limit of normal (ULN)

11. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) = 2.5 times ULN

12. Alkaline phosphatase = 2.5 times ULN

13. Creatinine clearance = 60 mL/min

14. Female patients of child-bearing potential (i.e. not surgically sterile, or not having spontaneous amenorrhea for at least 12 months) must agree to use an effective form of contraception during the treatment phase of the study.

15. Male patients must agree to use a condom with spermicide or their female partner must use an effective method of birth control.

16. Provide written informed consent in accordance with all applicable regulations and follow the study procedures. Patients must be capable of understanding the investigational nature, potential risks and benefits of the study.

Exclusion Criteria:

1. Prior treatment for locally advanced SCCHN (No prior surgery for SCCHN except nodal sampling or biopsy for study disease).

2. Patients with T1-2N1 or T1N2-3.

3. Pre-existing peripheral neuropathy = Grade 2 (motor or sensory).

4. Weight loss > 20% of body weight within 3 months of screening (unless purposeful).

5. Surgery = 28 days before randomization with the exception of feeding tube placement, dental extractions, central venous catheter placement, biopsies and nodal sampling.

6. Cancer of the nasopharynx, sinus, salivary gland or skin.

7. Previous radical radiation therapy (RT) to the head and neck region, excluding superficial RT for a non-melanomatous skin cancer.

8. Prior cancers, except: those diagnosed > 5 years ago with no evidence of disease recurrence and clinical expectation of recurrence of less than 5%; or successfully treated non-melanoma skin cancer; or carcinoma in situ of the cervix.

9. Significant intercurrent illness that will interfere with the chemotherapy or radiation therapy such as human immunodeficiency (HIV) infection, cardiac failure, pulmonary compromise (chronic obstructive pulmonary disease, pneumonia or respiratory decompensation) resulting in hospitalization within 12 months of screening, or active infection.

10. Any significant cardiac disease (e.g., New York Heart Association (NYHA) Class 3 or 4; myocardial infarction within the past 6 months; unstable angina; coronary angioplasty or coronary artery bypass graft (CABG) within the past 6 months; or uncontrolled atrial or ventricular cardiac arrhythmias..

11. High risk for poor compliance with therapy or follow up as assessed by the investigator.

12. Active herpes labialis, other lesions due to herpes simplex virus type I (HSV1) or dermatoses involving or within 50 cm of the lesions to be injected; active HSV1 lesions must have resolved before talimogene laherparepvec is injected.

13. Prior systemic chemotherapy for any type of cancer.

14. Patients for whom radiation therapy is contraindicated.

15. Pregnant or breast-feeding female. Confirmation that women of child-bearing potential are not pregnant. A negative serum ß- human chorionic gonadotropin (ß-hCG) pregnancy test result must be obtained during the screening period.

16. Currently enrolled and receiving an investigational agent in a clinical research study or received an investigational agent for any reason within 4 weeks prior to screening.

17. Require intermittent or chronic treatment with an anti-herpetic drug (e.g., acyclovir), other than intermittent topical use.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Carcinoma, Squamous Cell
• Head and Neck Cancer
• Head and Neck Neoplasms
• Squamous Cell Carcinoma

Intervention

Biological:
• Talimogene Laherparepvec
Administered by intratumoral injection

Radiation:
• Radiation
70 grays of radiation administered in 35 fractions over 7 weeks

Drug:
• Cisplatin
Administered by intravenous infusion

Locations

Country	Name	City	State
United Kingdom	The Royal Marsden Hospital	London
United States	Gabrail Cancer Center	Canton	Ohio
United States	Medical Univesity of South Carolina	Charleston	South Carolina
United States	Investigative Clinical Research of Indiana	Indianapolis	Indiana
United States	James Graham Brown Cancer Center, University of Louisville	Louisville	Kentucky
United States	VCU Massey Cancer Center	Richmond	Virginia

Sponsors (2)

Lead Sponsor	Collaborator
BioVex Limited	Amgen

Countries where clinical trial is conducted

United States,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	2-year Event-free Survival	Event-free survival is defined as the time from randomization until the first evidence of relapse, disease progression (local, regional, metastatic, or second primary), or death from any cause. Because this study was terminated with only 5 participants enrolled, and the study was terminated in the first year, this endpoint was not analyzed.	2 years	No
Secondary	Clinical Objective Response (cOR)	Tumor response was assessed by computed tomography (CT) scan according to a modified version of the revised Response Evaluation Criteria In Solid Tumors (RECIST) criteria (version 1.1). Objective response is defined as achieving a clinical partial response (cPR) or complete response (cCR). cCR is defined as disappearance of all baseline lesions. Any pathological lymph nodes must have a reduction in short axis to < 10 mm. cPR is defined as at least a 30% decrease in the sum of diameters of baseline lesions. Progressive disease (PD) is defined as at least a 20% increase in the sum of diameters of baseline lesions, taking as reference the smallest sum on study, and an absolute increase of at least 5 mm, or the appearance of any new lesions.; Because this study was terminated with 5 patients enrolled, data for this endpoint were summarized in by-patient listings only and the cOR rate was not calculated. Therefore a summary of response at the end of study is reported.	End of trial; the maximum time on study was 20 weeks.	No
Secondary	Metabolic Complete Response (mCR)	Response to therapy was assessed using [(18)F] fluorodeoxyglucose positron emission tomography (FDG PET) imaging to detect metabolically active tumors.; Metabolic complete response (mCR) is defined as complete disappearance of FDG uptake attributable to tumor compared to baseline scan.; Partial metabolic response (mPR) is defined as a > 40% decrease in specific uptake compared to the initial value in over half of the lesions.; Disease progression (mPD) is defined as a specific uptake increase in any lesion, appearance of new lesions, or presence of extended areas of disease activity.; Stable metabolic response (mSD) is defined as a decrease in uptake < 40% of the initial value of over half the lesions.; Because this study was terminated with 5 patients enrolled, data for this endpoint were summarized in by-patient listings only and the metabolic complete response rate was not calculated. Therefore a summary of metabolic response at end of study is reported.	End of study; the maximum time on study was 20 weeks.	No
Secondary	Pathologic Complete Response (mCR)	Response to therapy was assessed histopathologically from biopsies taken at surgery for those participants who had surgery prior to Week 22.; If no viable tumor cells were identified in surgical specimens (where the patient had surgery) the patient was classified as having a pathological complete response (pCR), and if viable tumor cells were identified, the patient was classified as having an incomplete pathologic response.; Because this study was terminated with 5 patients enrolled, data for this endpoint were summarized in by-patient listings only and the pathologic complete response rate was not calculated. Therefore a summary of participants with a pathologic complete response before the end of study is reported.	Up to Week 20	No
Secondary	Time to Locoregional Failure	Locoregional failure is defined as disease progression in the head and neck area at any time following completion of chemoradiotherapy.; Because this study was terminated with 5 subjects enrolled, time to locoregional failure was not analyzed.	Up to 27 months	No
Secondary	Time to Distant Failure	Distant failure is defined as disease progression at any site other than the head and neck area at any time following completion of chemoradiotherapy.; Because this study was terminated with 5 participants enrolled, time to distant failure was not analyzed.	Up to 27 months	No
Secondary	Time to Any Failure	Any failure is defined as disease progression at any site at any time following completion of chemoradiotherapy.; Because this study was terminated with 5 participants enrolled, time to any failure was not analyzed.	Up to 27 months	No
Secondary	Overall Survival	Overall survival is defined as the time from randomization to death from any cause.; Because this study was terminated with 5 participants enrolled, overall survival was not analyzed.	Up to 5 years after chemoradiotherapy	No
Secondary	Disease-specific Survival	Disease-specific survival is defined as the time from randomization to death of the patient due to the cancer under study.; Because this study was terminated with 5 participants enrolled, disease-specific survival was not analyzed.	Up to 5 years after chemoradiotherapy	No
Secondary	Participants With N1-2 Disease at Baseline Requiring Neck Dissection	Participants with Baseline Nl or N2 disease (lymph node metastasis not more than 6 cm in greatest dimension) with persistent disease as determined at the post chemoradiotherapy assessment of response were to proceed to neck dissection as permitted by the institution no later than Week 22. Since this study terminated prematurely neck dissection data were not collected or analyzed.	Weeks 19 - 21	No